An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer.

ABSTRACT:

Introduction

Several non-comparative phase II studies have evaluated metronomic oral vinorelbine (MOV) in metastatic non-small cell lung cancer (NSCLC) but the small size of each study limits their conclusions.

Purpose

To perform an individual patient-data metaanalysis of studies evaluating MOV in metastatic NSCLC in order to measure survival and safety of treatment with this regimen.

Methods

Studies were selected if (1) administration of oral vinorelbine thrice a week; (2) fixed daily dose comprised between 30 and 50 mg, and; (3) being published before October 4th 2018. Database encompassed 8 variables characterizing disease and demography, 3 informing therapy, and 12 describing survival and toxicity.

Results

Nine studies encompassing 418 patients fulfilled th

SUBMITTER: Pujol JL 

PROVIDER: S-EPMC6701879 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature